AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 80 filers reported holding AKERO THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $5,058,000 | -5.8% | 100,000 | -13.0% | 0.04% | -7.7% |
Q2 2023 | $5,369,350 | +45.2% | 115,000 | +9.5% | 0.04% | +50.0% |
Q1 2023 | $3,697,639 | -67.9% | 105,000 | -50.0% | 0.03% | -66.7% |
Q4 2022 | $11,507,461 | +512.1% | 210,000 | +136.3% | 0.08% | +550.0% |
Q4 2021 | $1,880,000 | -33.6% | 88,876 | -29.8% | 0.01% | -36.8% |
Q3 2021 | $2,831,000 | -9.9% | 126,667 | 0.0% | 0.02% | -13.6% |
Q2 2021 | $3,143,000 | +31.6% | 126,667 | +31.4% | 0.02% | +10.0% |
Q1 2021 | $2,389,000 | -3.9% | 96,398 | 0.0% | 0.02% | 0.0% |
Q4 2020 | $2,487,000 | -18.8% | 96,398 | -3.1% | 0.02% | -31.0% |
Q3 2020 | $3,063,000 | -22.2% | 99,500 | -37.0% | 0.03% | -31.0% |
Q2 2020 | $3,938,000 | +807.4% | 158,000 | +690.0% | 0.04% | +740.0% |
Q1 2020 | $434,000 | -2.3% | 20,000 | 0.0% | 0.01% | 0.0% |
Q4 2019 | $444,000 | -2.4% | 20,000 | 0.0% | 0.01% | -16.7% |
Q3 2019 | $455,000 | +19.4% | 20,000 | 0.0% | 0.01% | +20.0% |
Q2 2019 | $381,000 | – | 20,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 5,830,203 | $169,134,000 | 18.83% |
venBio Partners LLC | 2,444,311 | $70,909,000 | 6.74% |
Versant Venture Management, LLC | 617,727 | $17,920,000 | 3.49% |
Redmile Group, LLC | 2,513,746 | $72,924,000 | 1.03% |
Boxer Capital, LLC | 831,495 | $24,122,000 | 0.82% |
Integral Health Asset Management, LLC | 85,000 | $2,466,000 | 0.70% |
Vivo Capital, LLC | 673,280 | $19,532,000 | 0.69% |
SILVERARC CAPITAL MANAGEMENT, LLC | 32,000 | $928,000 | 0.51% |
Cormorant Asset Management, LP | 742,549 | $21,541,000 | 0.48% |
HHLR ADVISORS, LTD. | 1,656,673 | $48,060,000 | 0.48% |